Skip to main content
Erschienen in: Journal of Nuclear Cardiology 3/2020

20.05.2019 | Editorial

The quest to improve sudden cardiac death prediction using sympathetic innervation scintigraphy: Chasing a mirage?

verfasst von: Firas J. Al Badarin, MD, Poghni Peri-Okonny, MD MSc

Erschienen in: Journal of Nuclear Cardiology | Ausgabe 3/2020

Einloggen, um Zugang zu erhalten

Excerpt

Treatment options for patients with congestive heart failure (CHF) have evolved substantially over the last two decades to currently include various pharmaceutical and device-based therapies that improve clinical outcomes and quality of life in this population. For example, implantable cardiac defibrillators (ICDs) are now the cornerstone of primary prevention of sudden cardiac death (SCD) in patients with reduced left ventricular ejection fraction (LVEF),1 supported by significant improvement in overall survival in device recipients.2
Literatur
1.
Zurück zum Zitat Nanthakumar K, Epstein AE, Kay GN, Plumb VJ, Lee DS. Prophylactic implantable cardioverter-defibrillator therapy in patients with left ventricular systolic dysfunction: A pooled analysis of 10 primary prevention trials. J Am Coll Cardiol 2004;44:2166-72.CrossRef Nanthakumar K, Epstein AE, Kay GN, Plumb VJ, Lee DS. Prophylactic implantable cardioverter-defibrillator therapy in patients with left ventricular systolic dysfunction: A pooled analysis of 10 primary prevention trials. J Am Coll Cardiol 2004;44:2166-72.CrossRef
2.
Zurück zum Zitat Epstein AE, Dimarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 Guidelines for device-based therapy of cardiac rhythm abnormalities. Heart Rhythm 2008;5:e1-62.CrossRef Epstein AE, Dimarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 Guidelines for device-based therapy of cardiac rhythm abnormalities. Heart Rhythm 2008;5:e1-62.CrossRef
3.
Zurück zum Zitat Buxton AE. Should everyone with an ejection fraction less than or equal to 30% receive an implantable cardioverter-defibrillator? Not everyone with an ejection fraction < or = 30% should receive an implantable cardioverter-defibrillator. Circulation 2005;111:2537-49; discussion 2537-49. Buxton AE. Should everyone with an ejection fraction less than or equal to 30% receive an implantable cardioverter-defibrillator? Not everyone with an ejection fraction < or = 30% should receive an implantable cardioverter-defibrillator. Circulation 2005;111:2537-49; discussion 2537-49.
4.
Zurück zum Zitat Goldberger JJ, Cain ME, Hohnloser SH, American Heart Association/American College of Cardiology Foundation/Heart Rhythm Society Scientific Statement on Noninvasive Risk Stratification Techniques for Identifying Patients at Risk for Sudden Cardiac Death, et al. A scientific statement from the American Heart Association Council on Clinical Cardiology Committee on Electrocardiography and Arrhythmias and Council on Epidemiology and Prevention. J Am Coll Cardiol 2008;52:1179-99.CrossRef Goldberger JJ, Cain ME, Hohnloser SH, American Heart Association/American College of Cardiology Foundation/Heart Rhythm Society Scientific Statement on Noninvasive Risk Stratification Techniques for Identifying Patients at Risk for Sudden Cardiac Death, et al. A scientific statement from the American Heart Association Council on Clinical Cardiology Committee on Electrocardiography and Arrhythmias and Council on Epidemiology and Prevention. J Am Coll Cardiol 2008;52:1179-99.CrossRef
5.
Zurück zum Zitat Bax JJ, Kraft O, Buxton AE, et al. 123I-mIBG scintigraphy to predict inducibility of ventricular arrhythmias on cardiac electrophysiology testing: A prospective multicenter pilot study. Circ Cardiovasc Imaging 2008;1:131-40.CrossRef Bax JJ, Kraft O, Buxton AE, et al. 123I-mIBG scintigraphy to predict inducibility of ventricular arrhythmias on cardiac electrophysiology testing: A prospective multicenter pilot study. Circ Cardiovasc Imaging 2008;1:131-40.CrossRef
6.
Zurück zum Zitat Nagahara D, Nakata T, Hashimoto A, et al. Predicting the need for an implantable cardioverter defibrillator using cardiac metaiodobenzylguanidine activity together with plasma natriuretic peptide concentration or left ventricular function. J Nucl Med 2008;49:225-33.CrossRef Nagahara D, Nakata T, Hashimoto A, et al. Predicting the need for an implantable cardioverter defibrillator using cardiac metaiodobenzylguanidine activity together with plasma natriuretic peptide concentration or left ventricular function. J Nucl Med 2008;49:225-33.CrossRef
8.
Zurück zum Zitat Al Badarin FJ, Wimmer AP, Kennedy KF, Jacobson AF, Bateman TM. The utility of ADMIRE-HF risk score in predicting serious arrhythmic events in heart failure patients: Incremental prognostic benefit of cardiac 123I-mIBG scintigraphy. J Nucl Cardiol 2014;21:756-62; quiz 753-5, 755-63. Al Badarin FJ, Wimmer AP, Kennedy KF, Jacobson AF, Bateman TM. The utility of ADMIRE-HF risk score in predicting serious arrhythmic events in heart failure patients: Incremental prognostic benefit of cardiac 123I-mIBG scintigraphy. J Nucl Cardiol 2014;21:756-62; quiz 753-5, 755-63.
9.
Zurück zum Zitat Haïssaguerre M, Derval N, Sacher F, et al. Sudden Cardiac Arrest Associated with Early Repolarization. N Engl J Med 2008;358:2016-23.CrossRef Haïssaguerre M, Derval N, Sacher F, et al. Sudden Cardiac Arrest Associated with Early Repolarization. N Engl J Med 2008;358:2016-23.CrossRef
10.
Zurück zum Zitat Chen LS, Zhou S, Fishbein MC, Chen PS. New perspectives on the role of autonomic nervous system in the genesis of arrhythmias. J Cardiovasc Electrophysiol 2007;18:123-7.CrossRef Chen LS, Zhou S, Fishbein MC, Chen PS. New perspectives on the role of autonomic nervous system in the genesis of arrhythmias. J Cardiovasc Electrophysiol 2007;18:123-7.CrossRef
11.
Zurück zum Zitat Jacobson AF, Senior R, Cerqueira MD, et al. Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac events in heart failure. Results of the prospective ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) study. J Am Coll Cardiol 2010;55:2212-21.CrossRef Jacobson AF, Senior R, Cerqueira MD, et al. Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac events in heart failure. Results of the prospective ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) study. J Am Coll Cardiol 2010;55:2212-21.CrossRef
12.
Zurück zum Zitat Scholte AJ. The future of cardiac 123-I mIBG imaging. Eur J Nucl Med Mol Imaging 2016;43:2381-2.CrossRef Scholte AJ. The future of cardiac 123-I mIBG imaging. Eur J Nucl Med Mol Imaging 2016;43:2381-2.CrossRef
Metadaten
Titel
The quest to improve sudden cardiac death prediction using sympathetic innervation scintigraphy: Chasing a mirage?
verfasst von
Firas J. Al Badarin, MD
Poghni Peri-Okonny, MD MSc
Publikationsdatum
20.05.2019
Verlag
Springer International Publishing
Erschienen in
Journal of Nuclear Cardiology / Ausgabe 3/2020
Print ISSN: 1071-3581
Elektronische ISSN: 1532-6551
DOI
https://doi.org/10.1007/s12350-019-01741-9

Weitere Artikel der Ausgabe 3/2020

Journal of Nuclear Cardiology 3/2020 Zur Ausgabe

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.